BioCryst Pharmaceuticals is a biotechnology company focused on developing innovative therapies for rare diseases. Its core products include oral medications for conditions such as hereditary angioedema and other genetic disorders. The company primarily generates revenue through product sales and collaborations with other pharmaceutical firms. BioCryst's major business segments include research and development of new drug candidates and commercialization of existing therapies.
The investment profile of BioCryst Pharmaceuticals is more aligned with growth investors, given its focus on developing new therapies and the potential for significant revenue increases. The company is in a phase of expanding its product offerings, which may appeal to those seeking capital appreciation. However, the absence of dividends and the inherent risks associated with biotechnology investments suggest a cautious approach.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-10 | Hold | Sell | Weak fundamentals and negative momentum signal high risk. |
| 2026-08-29 | — | Hold | Positive revenue growth, but high EPS loss raises concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-10 | RBC Capital | Rating Downgraded | — → 11 | 8.805 |
| 2026-07-07 | RBC Capital | Target Raised | 13 → 14 | 10.17 |
| 2026-06-30 | Cantor Fitzgerald | Target Raised | 27 → 29 | 9.55 |
| 2026-06-30 | Jefferies | Target Raised | — → 17 | 9.55 |
| 2025-11-05 | JMP Securities | Target Lowered | 27 → 25 | 6.97 |
| 2025-11-04 | Barclays | Target Lowered | 11 → 9 | 6.86 |
| 2025-10-14 | RBC Capital | Update | — → 15 | 6.42 |
| 2025-10-14 | Jefferies | Target Raised | 14 → 15 | 6.42 |
